The acquisition is immediately transformative for Biogen's near-term growth, adding ~$689M in 2025 revenue from EMPAVELI/SYFOVRE and a nephrology pipeline. The $2B debt raise increases leverage but is manageable given Biogen's scale. Monitor Q2 earnings for updated 2026 guidance and SYFOVRE sales trajectory, which directly impacts CVR probability. The CVRs are non-transferable and not listed, so no direct trading vehicle exists.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $191.26entry
- T+1 · 6mo ago +0.55%α +1.78% · $192.32
- T+5 · 6mo ago −1.23%α −0.52% · $188.90
- T+20 · 5mo ago +4.60%α +5.46% · $200.05
- T+60 · 3mo ago +8.15%α +4.83% · $206.85
Price Chart
How similar events traded
Executive Summary
Biogen completed its $5.3B acquisition of Apellis Pharmaceuticals on May 14, 2026, adding commercial-stage products EMPAVELI and SYFOVRE. The deal was funded via a $2B term loan facility and cash. Apellis shareholders received $41/share plus one CVR per share, with potential milestone payments of up to $4/share tied to SYFOVRE net sales thresholds of $1.5B and $2.0B through 2031. The acquisition is expected to be accretive to Biogen's non-GAAP EPS in 2027.
Key Financial Metrics
Key Facts
- Biogen completed acquisition of Apellis Pharmaceuticals on May 14, 2026 for ~$5.3B in cash and CVRs.
- Apellis shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
- CVRs entitle holders to up to $4.00 per share in milestone payments tied to SYFOVRE net sales thresholds of $1.5B and $2.0B through 2031.
- Biogen borrowed the full $2B under a new term loan facility ($1B 364-day Tranche A, $1B 2-year Tranche B) to fund the acquisition.
- The acquisition adds EMPAVELI and SYFOVRE, which recorded $689M in combined net product revenue in 2025.
- Biogen expects the deal to be accretive to non-GAAP diluted EPS in 2027 and to materially increase non-GAAP EPS CAGR through the end of the decade.
- Approximately 105.7M shares (82.4% of outstanding) were validly tendered in the offer.
- Biogen estimates it would need ~$582M to pay the maximum aggregate CVR milestone amounts if all thresholds are achieved.
Financial Impact
Total acquisition consideration ~$5.3B in cash plus up to ~$582M in potential CVR milestone payments. Funded via $2B term loan and cash on hand.
Risk Factors
- SYFOVRE faces competition from other GA therapies (e.g., Avacincaptad pegol) which could pressure market share and net sales.
- CVR milestones are contingent on SYFOVRE achieving $1.5B and $2.0B annual net sales by 2031, no guarantee of achievement.
- Integration risk: combining Apellis' commercial and R&D operations with Biogen's existing infrastructure.
- Increased leverage from $2B term loan; financial covenant requires max consolidated leverage ratio of 3.75x (4.25x temporarily post-acquisition).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222908 |
| Document: d109852dex101.htm | 0001193125-26-222908 |
| Document: d109852dex991.htm | 0001193125-26-222908 |
| Document: d109852d8k.htm | 0001193125-26-222908 |
| Document: 0001193125-26-222908-index-headers.html | 0001193125-26-222908 |
| Document: 0001193125-26-222908-index.html | 0001193125-26-222908 |
| Document: 0001193125-26-222908.txt | 0001193125-26-222908 |
Track record
34 reports on BIIB
9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers